US halts trials of plasma transfusions for COVID-19 patients  | Inquirer News

US halts trials of plasma transfusions for COVID-19 patients 

/ 01:19 PM March 03, 2021

The exterior of EvergreenHealth Medical Center Kirkland, which treated many of the areas first COVID-19 patients, is seen in this drone aerial view on March 1, 2021 in Kirkland, Washington. Photo by David Ryder / GETTY IMAGES NORTH AMERICA / Getty Images via AFP

WASHINGTON – US health experts said Tuesday they are halting clinical trials of convalescent blood plasma in patients with mild to moderate Covid symptoms after preliminary results showed no benefit from the treatment.

The trial that began in August involved just over 500 people who went to emergency rooms but did not need to be hospitalized.


The people chosen for the study also had risk factors such as obesity, high blood pressure, diabetes or heart trouble.

Some of them received the treatment — blood plasma from people who had Covid and overcame it — and others got a placebo.


Doctors looked at how many needed additional care or outright hospitalization, or who died, in the 15 days after undergoing the treatment.

An independent group of experts determined that while the convalescent plasma intervention caused no harm, it was unlikely to benefit patients, the National Institutes of Health said.

Convalescent plasma is the liquid part of blood from a Covid patient that recovered. It contains anti-bodies produced by the body after being infected.

In late October a study carried out in India and published in the medical journal BMJ said the treatment offered limited effectiveness.

It did not reduce mortality or keep people with moderate Covid symptoms from developing a serious case.

More than 100,000 people have received the treatment in the US since the start of the pandemic and many more elsewhere in the world, the NIH said.

In late August, at the persistent request of then president Donald Trump, the US Food and Drug Administration granted emergency authorization for transfusions of blood plasma from recovered Covid patients to people who were hospitalized with the disease.


The then head of the FDA, Stephen Hahn, acknowledged an error at a press conference with Trump, saying he had cited figures that overestimated the benefits of the treatment.

The FDA recently restricted its emergency authorization to use of plasma only with a high concentration of antibodies and for patients hospitalized with early stages of Covid or with a limited ability to produce antibodies.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: blood plasma, coronavirus pandemic, COVID-19, US
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2021 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.